WENDY PREWETT
Acute Care Nurse Practitioner · TYLER, TX
Individual Active NPI 1134633266
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 559 | 384,295 | $22,903,622 | $9,867,606 | $7,845,378 |
| 2023 | 528 | 302,712 | $21,990,038 | $6,790,944 | $5,402,153 |
| 2022 | 320 | 151,222 | $14,509,706 | $3,127,515 | $2,489,073 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | 135,752 | $12 | $9 |
| J0485 | Injection, belatacept, 1 mg | 56,250 | $4 | $3 |
| J0174 | Injection, lecanemab-irmb, 1 mg | 32,400 | $1 | $1 |
| J2350 | Injection, ocrelizumab, 1 mg | 26,400 | $51 | $41 |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 15,700 | $18 | $14 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 14,700 | $10 | $8 |
| J3245 | Injection, tildrakizumab, 1 mg | 6,200 | $135 | $108 |
| J2357 | Injection, omalizumab, 5 mg | 5,670 | $38 | $30 |
| J2182 | Injection, mepolizumab, 1 mg | 5,400 | $30 | $24 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4,670 | $31 | $25 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 2,289 | $0 | $0 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 2,150 | $37 | $29 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Acute Care Nurse Practitioner | 363LA2100X | ✓ | AP135677 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Acute Care Nurse Practitioner providers in Texas
- NPI 1225703036
- NPI 1225049083
- NPI 1942221841
- NPI 1346718939
- NPI 1679354138
- NPI 1629467006
- NPI 1366051526
- NPI 1568071116
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.